A systematic review of platinum and taxane resistance from bench to clinic: an inverse relationship.
about
Taxane monotherapy for the treatment of platinum pre-treated epithelial ovarian cancerResistance to paclitaxel in a cisplatin-resistant ovarian cancer cell line is mediated by P-glycoproteinRetaining MKP1 expression and attenuating JNK-mediated apoptosis by RIP1 for cisplatin resistance through miR-940 inhibitionPaclitaxel plus oxaliplatin for recurrent or metastatic cervical cancer: a New York Cancer Consortium Study.Targeting the Achilles heel of multidrug-resistant cancer by exploiting the fitness cost of resistance.Synergy of 1,25-dihydroxyvitamin D3 and carboplatin in growth suppression of SKOV-3 cells.Anti-MUC1 monoclonal antibody (C595) and docetaxel markedly reduce tumor burden and ascites, and prolong survival in an in vivo ovarian cancer model.Activation of the MEK-S6 pathway in high-grade ovarian cancers.Effects of SC-560 in combination with cisplatin or taxol on angiogenesis in human ovarian cancer xenograftsBenzene-poly-carboxylic acid complex, a novel anti-cancer agent induces apoptosis in human breast cancer cells.Synergistic cytotoxicity of cisplatin and Taxol in overcoming Taxol resistance through the inhibition of LDHA in oral squamous cell carcinoma.Synergistic anticancer effect of cisplatin and Chal-24 combination through IAP and c-FLIPL degradation, Ripoptosome formation and autophagy-mediated apoptosis.Synthesis and anti-cancer activities of a water soluble gold(III) porphyrin.Quantitative proteomic analysis of mitochondria from human ovarian cancer cells and their paclitaxel-resistant sublinesReduced accumulation of platinum drugs is not observed in drug-resistant ovarian cancer cell lines derived from cisplatin-treated patientsUnderstanding drugs in breast cancer through drug sensitivity screeningDistinct genetic alterations occur in ovarian tumor cells selected for combined resistance to carboplatin and docetaxelTargeted inhibition of phosphatidyl inositol-3-kinase p110β, but not p110α, enhances apoptosis and sensitivity to paclitaxel in chemoresistant ovarian cancers.Cataloging antineoplastic agents according to their effectiveness against platinum-resistant and platinum-sensitive ovarian carcinoma cell lines.Photoimmunotherapy and irradiance modulation reduce chemotherapy cycles and toxicity in a murine model for ovarian carcinomatosis: perspective and results.An Engineered Arginase FC Protein Inhibits Tumor Growth In Vitro and In Vivo.Dysregulation of miR-106a and miR-591 confers paclitaxel resistance to ovarian cancer.Sigma-2 receptor ligand as a novel method for delivering a SMAC mimetic drug for treating ovarian cancer.LC-MS Based Sphingolipidomic Study on A2780 Human Ovarian Cancer Cell Line and its Taxol-resistant Strain.Can the status of the breast and ovarian cancer susceptibility gene 1 product (BRCA1) predict response to taxane-based cancer therapy?Is resistance useless? Multidrug resistance and collateral sensitivity.New emerging drugs targeting the genomic integrity and replication machinery in ovarian cancer.The role of Tau protein in resistance to paclitaxel.Genetic testing today.Ixabepilone for the treatment of endometrial cancer.A Human Head and Neck Squamous Cell Carcinoma Cell Line with Acquired cis-Diamminedichloroplatinum-Resistance Shows Remarkable Upregulation of BRCA1 and Hypersensitivity to Taxane.Cisplatin resistance in cell models: evaluation of metallomic and biological predictive biomarkers to address early therapy failure.Down-regulated expression of miR-134 contributes to paclitaxel resistance in human ovarian cancer cells.Notch3-specific inhibition using siRNA knockdown or GSI sensitizes paclitaxel-resistant ovarian cancer cells.The relationship between platinum drug resistance and epithelial-mesenchymal transition.BnRCH gene inhibits cell growth of Hela cells through increasing the G2 phase of cell cycle.Shell crosslinked knedel-like nanoparticles for delivery of cisplatin: effects of crosslinking.CD10-/ALDH- cells are the sole cisplatin-resistant component of a novel ovarian cancer stem cell hierarchy.Salen-Mn compounds induces cell apoptosis in human prostate cancer cells through promoting AMPK activity and cell autophagy.LncRNA NEAT1 contributes to paclitaxel resistance of ovarian cancer cells by regulating ZEB1 expression via miR-194.
P2860
Q24235072-7B784794-F6C4-4B96-9E15-321FFB4CB69BQ28481246-7ACC439B-11C6-4CA0-B641-8C29E8E7A42CQ33576820-51F62C2B-5F51-44C5-9175-D01F92B4F2E1Q33653575-FADA5E2B-A218-4ABC-8CC5-DAF54FA47A87Q33763765-41FB3A44-A781-4599-AB23-56CD4493515AQ33967557-EEFD9EB1-0D4E-4495-88C4-A5AC704EEB82Q34023497-D3E8A4AD-A126-4583-AC8D-D1E4F2FF56A5Q34339010-3629973D-0EA8-4B46-A79D-9F289FABCC15Q34487087-E88C2C1B-C770-424A-ADE3-F258623BF382Q35093497-23DFA1E6-9D83-43A2-9E1B-528DD5D13B37Q35167498-80B87748-8095-4526-B370-984481687AA7Q35176405-AC9BCBC3-7AC3-4885-BBC2-D5F98FDDD3E7Q35530076-515B1F48-E4C3-4FFC-8B22-DBBA17E7F916Q35649272-2635761D-DDE0-463C-A801-08191FA1E4CCQ35744147-7FCBDFD6-9DB8-41C4-BA1E-9549BB000E07Q36234079-C5EC16A2-189A-4CA4-8A8A-59835E63B4AEQ36521792-E3950544-B06D-4F47-A303-843A400B99B2Q36705677-4B0B4F5D-0A2A-49A6-A001-58B9FC719334Q36787695-52C732AC-ED3D-4501-BDC2-453D364F1E3DQ36790826-EF9B3905-050B-41ED-9AEC-FE5C13D5AFB6Q36869275-8A51EF5E-B22A-4CAB-9879-0C511C4809A1Q37040599-FF884E36-1E97-4E57-8266-D8D9D5327B76Q37279268-E9DD02AD-9F6C-4F8C-970E-543DBDA5AC39Q37310661-AE6B2C69-616B-443F-954D-D3CF463FEB2EQ37349840-2B25FB5E-66BA-4385-B790-70A8EB4D3F6DQ37414081-864409DE-8C31-450C-9A33-A95D5143EE35Q37809986-F5FFB21B-47F3-4C3A-ADA1-5D8458D486F6Q37895519-E04ECF23-2E6E-4C7C-B29A-83CBEB015AF3Q38230196-77F464AD-09CB-4060-B500-EE543A5437D1Q38763500-85998DF9-C3EC-4AC5-B9A3-9FAFE88D7D4DQ38791316-2BC760B2-112D-4B66-8A57-03A511FD3FA5Q38829177-14D53C69-1A85-454F-A7D1-1CBF54449A0FQ38835883-B54ED3A4-272D-498D-AE5B-0ED285F10A33Q38849720-79F2E41A-8037-498D-9029-96904A053A0DQ39061847-ECC18D88-5BDF-452F-A01A-1F95448FD5D5Q39450806-CB65C84A-2E8D-45C0-8D84-045AE742D9C4Q43602743-E89ADEF6-1149-4FC0-9836-73FBABA2FA18Q45046872-A707A5D5-F52C-4A84-AA71-C7302A5C6E2FQ46106014-157C7BEB-68FC-462B-8188-5BD4166EB7D3Q47163226-473785BA-63FC-4C41-92C0-977EF41E1501
P2860
A systematic review of platinum and taxane resistance from bench to clinic: an inverse relationship.
description
2007 nî lūn-bûn
@nan
2007 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
A systematic review of platinu ...... inic: an inverse relationship.
@ast
A systematic review of platinu ...... inic: an inverse relationship.
@en
A systematic review of platinu ...... inic: an inverse relationship.
@nl
type
label
A systematic review of platinu ...... inic: an inverse relationship.
@ast
A systematic review of platinu ...... inic: an inverse relationship.
@en
A systematic review of platinu ...... inic: an inverse relationship.
@nl
prefLabel
A systematic review of platinu ...... inic: an inverse relationship.
@ast
A systematic review of platinu ...... inic: an inverse relationship.
@en
A systematic review of platinu ...... inic: an inverse relationship.
@nl
P2093
P1476
A systematic review of platinu ...... inic: an inverse relationship.
@en
P2093
Britta Stordal
Nick Pavlakis
Ross Davey
P304
P356
10.1016/J.CTRV.2007.07.013
P577
2007-09-18T00:00:00Z